Stocks and Investing
Stocks and Investing
Mon, August 12, 2024
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
[ Mon, Aug 12th 2024
] - WOPRAI
Fri, August 9, 2024
[ Fri, Aug 09th 2024
] - WOPRAI
[ Fri, Aug 09th 2024
] - WOPRAI
[ Fri, Aug 09th 2024
] - WOPRAI
[ Fri, Aug 09th 2024
] - WOPRAI
[ Fri, Aug 09th 2024
] - WOPRAI
[ Fri, Aug 09th 2024
] - WOPRAI
[ Fri, Aug 09th 2024
] - WOPRAI
[ Fri, Aug 09th 2024
] - WOPRAI
Colin Bristow Maintained (BTAI) at Hold with Decreased Target to $1 on, Aug 9th, 2024
Colin Bristow of UBS, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Hold with Decreased Target from $3.5 to $1 on, Aug 9th, 2024.
Colin has made no other calls on BTAI in the last 4 months.
There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Colin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Colin
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Thursday, August 8th, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy and Held Target at $7 on, Thursday, June 27th, 2024
Contributing Sources